



FF Pharmaceuticals closes series A financing round

Utrecht, The Netherlands / Diepenbeek, Belgium - January 23, 2013 - FF Pharmaceuticals BV, a recently founded Dutch biopharmaceutical company, announces the closing of a first installment of its series A financing round, raising a total of EUR 4 mio.

FF Pharmaceuticals will focus on the development of novel disease-modifying therapeutics for the treatment of inflammatory diseases. The company's lead product, PG102, is a clinical stage humanized anti-CD-40 monoclonal antibody that was in-licensed from PanGenetics BV. The financing raised in this series A round will allow FF Pharmaceuticals to initiate the clinical validation of PG102 for the treatment of various autoimmune diseases and inflammatory conditions.

The financing round was led by LRM and co-led by Vesalius Biocapital. PMV (via its Vinnof subsidiary) also participated in the round. Nico Vandervelpen, Head of Life Sciences at LRM, Stéphane Verdood, Managing Director at Vesalius Biocapital and Bram Vanparys, Investment Manager at PMV-Vinnof will join the company's supervisory board that consist further of PanGenetics founder Dr. Jeff Price and Dr. Kevin Johnson, previously CEO of PanGenetics and now Partner at Index Ventures. Nico Vandervelpen is appointed as chairman of the board.

FF Pharmaceuticals BV has its headquarters in Utrecht, the Netherlands and will set up a subsidiary at BioVille, the life sciences incubator in Diepenbeek, Belgium, to coordinate its development activities.

"We are very excited about the potential of PG102. With its unique mechanism of action, this drug candidate holds significant potential as a truly disease modifying agent in chronic inflammatory conditions and autoimmune diseases." comments Nico Vandervelpen.

Mark de Boer, CEO of FF Pharmaceuticals said: "I am pleased with the successful completion of this start-up financing and the long term commitment from our investors that will allow us to advance our lead product candidate towards clinical proof-of-concept."



FF Pharma

About LRM

LRM is a profit-oriented investor, offering entrepreneurs a unique combination of venture capital and real estate.

LRM is a generalist, but has developed specific competencies in ICT, Life Sciences and Cleantech. LRM's activities contribute to the economic development and general employment in the province of Limburg. It targets all sectors and companies, from starting companies to growing SMEs and larger businesses. Access to LRM runs via five domains: ICT & Media, Life Sciences, Cleantech & Energy, SMEs and Large Businesses.

www.lrm.be

About Vesalius Biocapital Partners

Vesalius Biocapital Partners invests in companies active in human health through venture capital funds raised since 2007. Vesalius Biocapital offers venture capital to young European innovative life science companies and has contributed to developing eleven companies since inception, one of which was acquired through a trade sale. With over €140 million under management in two funds, Vesalius Biocapital Partners plays the role of lead investor in the large majority of its financing rounds.

www.vesaliusbiocapital.com

About PMV-VINNOF

Vinnof (Vlaams Innovatiefonds - Flemish Innovation Fund) provides venture capital to young, innovative companies and start-ups based in Flanders. Vinnof is a 100 % subsidiary of the Flemish investment company PMV NV.

www.pmv.eu

For further information please contact:

Marc de Boer, PhD
Chief Executive Officer
FF Pharmaceuticals BV
Tel. +32 11 286917
info@ffpharma.com